Search
A new MSK study finds that in colorectal cancer, not all regulatory T cells are created equal. One subtype suppresses cancer growth while another aids it. The findings could help improve immunotherapy treatment for the majority of patients with colorectal cancer, and potentially for other cancers.
Advances in diagnosis and treatment, especially those made over the past ten years, have played a significant role in the decline in cancer deaths. Learn about those advances — and what to expect in the next ten years.
Read about MSK research that sheds light on how the innate immune system interacts with developing cancer cells.
Isabel Lam, a 2016 alumnae of Gerstner Sloan Kettering, has been awarded the Chairman’s Prize for her first-author paper “Nonparadoxical evolutionary stability of the recombination initiation landscape in yeast,” published in Science in 2015.
Sixth-year graduate student Alexandria Miller was awarded the Chairman’s Prize for her first-author paper accepted for publication in the January 28, 2012 issue of Science.
Memorial Sloan Kettering Cancer Center today announced that its state-of-the-art cancer care pavilion currently under construction will be named The Kenneth C. Griffin Pavilion at Memorial Sloan Kettering Cancer Center.
Why endometrial cancer is especially dangerous for Black women.
Patients with profound immunosuppression after undergoing hematopoietic stem-cell transplantation or receiving chimeric antigen receptor (CAR) T cell therapy may shed viable SARS-CoV-2 for at least two months.
Learn how exercise can help many people live longer after they are diagnosed with cancer, according to a new study from MSK's Exercise-Oncology Service.
During the plenary session at the American Association for Cancer Research’s (AACR) virtual annual meeting I on Tuesday, April 28, Memorial Sloan Kettering (MSK) expert Louis P. Voigt, MD, Intensivist, spoke about disparities with cancer and COVID-19 patients.